Table 4.
Drug susceptibility of P. kudriavzevii to azoles.
| Author | Year | MIC method | Fluconazole | Isavuconazole | Itraconazole | Posaconazole | Voriconazole |
|---|---|---|---|---|---|---|---|
| Arendrup27 | 2013 | EUCAST (EUCAST BP, CLSI BP for itraconazole) | (n = 52) 0% S |
ND | (n = 52) 28.8% S |
(n = 52) 3.8% S |
(n = 52) 11.5% S |
| Arikan-Akdagli75 | 2019 | CLSI | (n = 52) GM MIC (range): 27.64 (8- >64), 100% R |
ND | 0.17 (≤0.015-0.5), 0% non-WT |
0.14 (≤0.03-1), 1.9% non-WT |
0.07 (0.03-0.125), 100% S |
| Badiee19 | 2017 | CLSI (susceptibility based on CLSI BP, or ECV) | GM MIC (range): 17.9 (2-64), >64 (5%) non-WT |
ND | 0.2 (0.064-1), 33.3% R |
0.126 (0.032-0.5), >0.5 (5%) non-WT |
0.284 (0.032-16), 20% R |
| Castanheira28 | 2020 | CLSI | ND | ND | ND | 0% non-WT | 1.3% R (5% R in North America, n = 20) |
| Castanheira29 | 2014 | CLSI | ND | ND | ND | 5.6% R | 2.8% R |
| Castanheira24 | 2014 | CLSI | ND | MIC/MEC range: 0.12-2, MIC/MEC50: 0.5, MIC/MEC90: 0.5, % not available |
0.25-4, 0.25, 0.5, 3.1% non-WT |
0.12-2, 0.25, 0.5, 6.3% non-WT |
0.12-4, 0.25, 0.25, 3.1% non-WT |
| Chen77 | 2017 | Sensititre YeastOne | MIC range: 32-128, MIC50: 64, MIC90: 64 Considered intrinsically resistant |
ND | ND | ND | 0.12-0.5, 0.5, 0.5, 0% R 100% S |
| Desnos-Ollivier78 | 2019 | EUCAST | MIC range:16- ≥64, MIC50: 32, MIC90: 64 % R not available (considered intrinsically resistant) |
MIC range:0.015-1, MIC50: 0.125, MIC90: 0.25 %isolates with MIC>MIC90: 6.58% |
ND | ND | ND |
| Fuller36 | 2019 | CLSI | mode MIC: 8, MIC90: 16 |
ND | ND | ND | MIC90: 0.25 |
| Seyoum26 | 2020 | VITEK 2 compact system |
n = 14, 100% R |
ND | ND | ND | 0% R |
| Hrabovsky79 | 2017 | EUCAST | (n = 40 isolates for invasive disease) MIC range: 2-256, MIC50: 256, MIC90: 256 100% R |
ND | ND | ND | 0.094-4, 0.5, 1,5% R |
| Israel21 | 2019 | CLSI | NA (considered intrinsically resistant) | ND | ND | ND | (n = 54), 3.8% R |
| Kaur12 | 2020 | CLSI | ND | ND | (n = 82 paediatric isolates) GM MIC (range): 0.31 (0.12-0.5), MIC50: 0.25, MIC90: 0.5 |
0.24 (0.06-0.5), 0.25, 0.5 |
0.41 (0.05-8), 0.25, 0.25 |
| Kaur23 | 2020 | CLSI | For 2014-2018 period: 40.5% R |
ND | 4.2% R | 0% R | 1.9% R |
| Omrani14 | 2014 | CLSI |
n = 13, 0% S |
ND | ND | ND |
n = 6, 100% S |
| Pfaller80 | 2011 | CLSI | ND | ND | ND |
n = 16 ICU, 0% R, n = 20 non-ICU, 0% R |
n = 16 ICU, 0% R, n = 20 non-ICU, 0% R |
| Pfaller25 | 2015 | CLSI | MIC/MEC range: 8- >128, MIC50: 32, MIC90: 64, Intrinsically resistant. |
MIC/MEC range: 0.12-4, MIC50: 0.5, MIC90: 1 |
MIC/MEC range: 0.25-2, MIC50: 0.5, MIC90: 1, 2.7% non-WT, 97.3% WT |
MIC/MEC range: 0.25-1, MIC50: 0.5, MIC90: 0.5,2.7% non-WT, 97.3% WT |
2.7%R, 94.6% S |
| Salse81 | 2019 | E-test |
n = 414, mode MIC: >256 |
ND | ND | ND |
n = 575, mode MIC: 0.5 |
| Sasso37 | 2017 | E-test (CLSI BP) | 100% R (n = 48) (averaged for 2007-2016) |
ND | ND | ND | 79.4% S (n = 55) 29.6% I (n = 47) (averaged for 2007–2016) |
| Tóth22 | 2019 | CLSI | mode MIC (range): 32 (8- >32), MIC50: 32, MIC90: >32%, R ND |
ND | ND | ND | ND |
Data are reported as they appear in source documents. Susceptibility is expressed as mg/l unless indicated otherwise. BP=breakpoint, CLSI=Clinical and Laboratory Standards Institute, ECV=epidemiological cutoff value, EUCAST= European Committee on Antimicrobial Susceptibility Testing, R=resistant, S=susceptible, S-DD=susceptible dose-dependent, I=intermediate, MIC= minimum inhibitory concentration, MEC=minimum effective concentration, GM= geometric mean, NA/ND= not applicable / not done, MIC50=MIC required to inhibit the growth of 50% of isolates, MIC90=MIC required to inhibit the growth of 90% of isolates, ND= no data, Non-WT = non wild-type.